Cargando…

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

BACKGROUND: This phase I, open-label, first-in-human study determined dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of PD 0332991, an oral cyclin-dependent kinase 4/6 inhibitor with potent anti-proliferative activity in vitro/vivo. METHODS: A total of 33 patients with retinoblasto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwartz, G K, LoRusso, P M, Dickson, M A, Randolph, S S, Shaik, M N, Wilner, K D, Courtney, R, O'Dwyer, P J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111206/ https://www.ncbi.nlm.nih.gov/pubmed/21610706 http://dx.doi.org/10.1038/bjc.2011.177

Ejemplares similares

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
por: Rasschaert, M, et al.
Publicado: (2007)

High cyclin B1 expression is associated with poor survival in breast cancer
por: Aaltonen, K, et al.
Publicado: (2009)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt
por: Szegezdi, E, et al.
Publicado: (2006)

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
por: Yao, K, et al.
Publicado: (2005)

Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
por: Broadhead, M L, et al.
Publicado: (2011)

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses
por: Dolly, Saoirse O, et al.
Publicado: (2017)

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
por: Johnson, N, et al.
Publicado: (2010)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21
por: He, G, et al.
Publicado: (2006)

Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation
por: Spagnuolo, C, et al.
Publicado: (2011)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients
por: Russo, M, et al.
Publicado: (2010)

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells
por: Vaz, A P, et al.
Publicado: (2014)

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
por: Gottlieb, D J, et al.
Publicado: (2006)

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
por: Lorusso, D, et al.
Publicado: (2012)

Effects of adiponectin on breast cancer cell growth and signaling
por: Grossmann, M E, et al.
Publicado: (2008)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
por: Someya, M, et al.
Publicado: (2011)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt
por: Pal, I, et al.
Publicado: (2014)

Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
por: Schulz, P, et al.
Publicado: (2008)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration
por: Thomas, Z I, et al.
Publicado: (2011)

Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1
por: Yuen, H-F, et al.
Publicado: (2010)

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel
por: Uzoh, C C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7h4uhsc6pmuho3cbd7983nf4ub